Literature DB >> 15792521

Erythropoietin and erythropoietin receptor expression after experimental spinal cord injury encourages therapy by exogenous erythropoietin.

Giovanni Grasso1, Alessandra Sfacteria, Marcello Passalacqua, Antonio Morabito, Michele Buemi, Battesimo Macrì, Michael L Brines, Francesco Tomasello.   

Abstract

OBJECTIVE: Erythropoietin (EPO) is a pleiotropic cytokine originally identified for its role in erythropoiesis. Recent studies have demonstrated that EPO and its receptor (EPO-R) are expressed in the central nervous system, where EPO exerts neuroprotective functions. Because the expression of the EPO and EPO-R network is poorly investigated in the central nervous system, the aim of the present study was to investigate whether the resident EPO and EPO-R network is activated in the injured nervous system.
METHODS: A well-standardized model of compressive spinal cord injury in rats was used. EPO and EPO-R expression was determined by immunohistochemical analysis at 8 hours and at 2, 8, and 14 days in the spinal cord of injured and noninjured rats.
RESULTS: In noninjured spinal cord, weak immunohistochemical expression of EPO and EPO-R was observed in neuronal and glial cells as well as in endothelial and ependymal cells. In injured rats, a marked increase of expression of EPO and EPO-R was observed in neurons, vascular endothelium, and glial cells at 8 hours after injury, peaking at 8 days, after which it gradually decreased. Two weeks after injury, EPO immunoreactivity was scarcely detected in neurons, whereas glial cells and vascular endothelium expressed strong EPO-R immunoreactivity.
CONCLUSION: These observations suggest that the local EPO and EPO-R system is markedly engaged in the early stages after nervous tissue injury. The reduction in EPO immunoexpression and the increase in EPO-R staining strongly support the possible usefulness of a therapeutic approach based on exogenous EPO administration.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15792521     DOI: 10.1227/01.neu.0000156493.00904.7e

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  24 in total

1.  Increased erythropoietin production after myocardial infarction in mice.

Authors:  M Mengozzi; R Latini; M Salio; A Sfacteria; G Piedimonte; J G Gerwien; M Leist; A L Siren; P Ghezzi; S Chimenti
Journal:  Heart       Date:  2006-06       Impact factor: 5.994

2.  Dose-dependent neurorestorative effects of delayed treatment of traumatic brain injury with recombinant human erythropoietin in rats.

Authors:  Yuling Meng; Ye Xiong; Asim Mahmood; Yanlu Zhang; Changsheng Qu; Michael Chopp
Journal:  J Neurosurg       Date:  2011-04-15       Impact factor: 5.115

3.  Vector-mediated expression of erythropoietin improves functional outcome after cervical spinal cord contusion injury.

Authors:  S Wang; Z Wu; P Chiang; D J Fink; M Mata
Journal:  Gene Ther       Date:  2011-11-03       Impact factor: 5.250

4.  Investigation of the protective effect of erythropoietin on spinal cord injury in rats.

Authors:  Zhenghua Hong; Huaxing Hong; Haixiao Chen; Zhangfu Wang; Dun Hong
Journal:  Exp Ther Med       Date:  2011-06-14       Impact factor: 2.447

5.  Erythropoietin Enhanced Recovery After Traumatic Nerve Injury: Myelination and Localized Effects.

Authors:  Leigh Sundem; Kuang-Ching Chris Tseng; Haiyan Li; John Ketz; Mark Noble; John Elfar
Journal:  J Hand Surg Am       Date:  2016-09-01       Impact factor: 2.230

6.  Endogenous erythropoietin as part of the cytokine network in the pathogenesis of experimental autoimmune encephalomyelitis.

Authors:  Manuela Mengozzi; Ilaria Cervellini; Paolo Bigini; Sara Martone; Antonella Biondi; Rosetta Pedotti; Barbara Gallo; Sara Barbera; Tiziana Mennini; Mariaserena Boraso; Marina Marinovich; Edwige Petit; Myriam Bernaudin; Roberto Bianchi; Barbara Viviani; Pietro Ghezzi
Journal:  Mol Med       Date:  2008-07-30       Impact factor: 6.354

7.  Optimal neuroprotection by erythropoietin requires elevated expression of its receptor in neurons.

Authors:  Pascal E Sanchez; Raafat P Fares; Jean-Jacques Risso; Chantal Bonnet; Sandrine Bouvard; Marion Le-Cavorsin; Béatrice Georges; Colette Moulin; Amor Belmeguenai; Jacques Bodennec; Anne Morales; Jean-Marc Pequignot; Etienne-Emile Baulieu; Robert A Levine; Laurent Bezin
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-03       Impact factor: 11.205

8.  Impaired synthesis of erythropoietin, glutamine synthetase and metallothionein in the skin of NOD/SCID/gamma(c)(null) and Foxn1 nu/nu mice with misbalanced production of MHC class II complex.

Authors:  L Danielyan; S Verleysdonk; M Buadze; C H Gleiter; G H Buniatian
Journal:  Neurochem Res       Date:  2009-10-14       Impact factor: 3.996

9.  Delayed administration of erythropoietin reducing hippocampal cell loss, enhancing angiogenesis and neurogenesis, and improving functional outcome following traumatic brain injury in rats: comparison of treatment with single and triple dose.

Authors:  Ye Xiong; Asim Mahmood; Yuling Meng; Yanlu Zhang; Changsheng Qu; Timothy Schallert; Michael Chopp
Journal:  J Neurosurg       Date:  2010-09       Impact factor: 5.115

Review 10.  Erythropoietin in spinal cord injury.

Authors:  Georgios K Matis; Theodossios A Birbilis
Journal:  Eur Spine J       Date:  2008-11-22       Impact factor: 3.134

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.